Want to see GB:VRCI full AI Analyst Report?
Top Page
Verici Dx Plc
(LSE:VRCI)
Select Model
Select Model
Rating:44Neutral
Price Target:
0.36 p
▼(-49.44% Downside)
Action:Reiterated
Date:06/30/26
The score is primarily held back by persistent and widening losses alongside accelerating cash burn, which increases financing risk. Strong revenue growth and low leverage provide some support, but valuation signals are limited by unprofitability and technical signals are unavailable due to missing indicators.
Positive Factors
Strong revenue acceleration
Sustained, multi-year revenue acceleration signals strengthening product adoption and market penetration in transplant diagnostics. Durable top-line growth provides a foundation for scaling lab partnerships, negotiating payor coverage, and leveraging fixed-cost absorption to improve long-term profitability prospects.
Negative Factors
Worsening operating cash burn
Significantly increased negative operating and free cash flow is a persistent structural weakness that raises financing risk. Continued cash burn forces reliance on external funding, can dilute shareholders, and constrains the company's ability to invest in commercialization or weather slower adoption periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue acceleration
Sustained, multi-year revenue acceleration signals strengthening product adoption and market penetration in transplant diagnostics. Durable top-line growth provides a foundation for scaling lab partnerships, negotiating payor coverage, and leveraging fixed-cost absorption to improve long-term profitability prospects.
Read all positive factors
Verici Dx Plc (VRCI) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£8.58M
Dividend YieldN/A
Average Volume (3M)6.85M
Price to Earnings (P/E)―
Beta (1Y)-1.50
Revenue Growth5.41%
EPS Growth39.06%
CountryUK
Employees19
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.01
Shares Outstanding2,287,311,300
10 Day Avg. Volume9,044,876
30 Day Avg. Volume6,845,005
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.20
Price to Sales (P/S)2.08
P/FCF Ratio-0.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£4.90M
Verici Dx Plc Business Overview & Revenue Model
Company Description
Verici Dx plc is an immuno-diagnostics company primarily focused on the kidney transplantation sector. The firm specializes in creating both predictive and diagnostic assays for patients who have undergone kidney transplants. Its development pipel...
How the Company Makes Money
Verici Dx makes money by developing and commercializing molecular diagnostic tests for transplant patient management. Revenue is generated primarily through sales of its diagnostic testing services (i.e., when its tests are ordered and performed f...
Verici Dx Plc Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.74M | 3.34M | 1.01M | 0.00 | 0.00 |
| Gross Profit | 2.32M | 3.34M | 1.01M | 0.00 | 0.00 |
| EBITDA | ― | -5.15M | -7.88M | -10.50M | -7.15M |
| Net Income | -7.08M | -5.87M | -8.73M | -11.36M | -8.33M |
Balance Sheet | |||||
| Total Assets | 7.94M | 7.49M | 7.44M | 14.30M | 13.79M |
| Cash, Cash Equivalents and Short-Term Investments | 3.34M | 4.06M | 2.65M | 9.80M | 10.34M |
| Total Debt | 197.07K | 371.00K | 540.00K | 700.00K | 0.00 |
| Total Liabilities | 1.44M | 2.23M | 3.88M | 2.80M | 1.80M |
| Stockholders Equity | 6.51M | 5.26M | 3.56M | 11.51M | 11.98M |
Cash Flow | |||||
| Free Cash Flow | -8.39M | -6.21M | -7.39M | -11.38M | -7.30M |
| Operating Cash Flow | -8.39M | -6.02M | -7.16M | -10.07M | -6.34M |
| Investing Cash Flow | -192.97K | 61.00K | -231.00K | -1.31M | -965.86K |
| Financing Cash Flow | 7.87M | 7.32M | -27.00K | 12.67M | -73.55K |
Verici Dx Plc Technical Analysis
Negative
0.72
Price Trends
0.43
Negative
0.50
Negative
0.62
Negative
Market Momentum
-0.01
Negative
20.85
Positive
60.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VRCI, the sentiment is Negative. The current price of 0.72 is above the 20-day moving average (MA) of 0.38, above the 50-day MA of 0.43, and above the 200-day MA of 0.62, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 20.85 is Positive, neither overbought nor oversold. The STOCH value of 60.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:VRCI.
Verici Dx Plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | £111.89M | 55.32 | 3.01% | ― | 2.73% | -65.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £25.91M | -12.20 | -55.91% | ― | 40.37% | -13.70% | |
49 Neutral | £20.87M | -1.19 | -153.92% | ― | 65.60% | 74.84% | |
45 Neutral | £10.05M | -0.33 | 425.97% | ― | ― | ― | |
44 Neutral | £8.58M | -0.40 | -122.54% | ― | 5.41% | 39.06% | |
38 Underperform | £4.08M | -0.10 | -316.67% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
GB:VRCI
Verici Dx Plc
0.38
-0.75
-66.67%
GB:EKF
EKF Diagnostics Holdings
26.00
-0.20
-0.76%
GB:GDR
Genedrive
1.30
-0.08
-6.00%
GB:OBD
Oxford BioDynamics
0.10
-0.21
-68.33%
GB:RENX
Renalytix
2.30
-4.70
-67.14%
GB:ABDX
Abingdon Health PLC
10.25
3.25
46.43%
Verici Dx Plc Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Verici Dx accelerates Tutivia rollout as revenues rise and U.S. transplant test adoption grows
Positive
Jun 29, 2026
Verici Dx reported FY25 revenues of $3.7 million, driven by $2.9 million in recognised Tutivia sales following its commercial rollout and $0.8 million in licence income, alongside equity raises that extended its cash runway to the end of 2026 desp...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Verici Dx Wins New York Approval, Securing Nationwide U.S. Access for Tutivia Transplant Test
Positive
Jun 24, 2026
Verici Dx has secured clinical laboratory certification from the New York State Department of Health’s highly rigorous CLEP programme, completing its authorisation to provide laboratory testing services in all 50 U.S. states and the District...
Delistings and Listing ChangesPrivate Placements and FinancingShareholder Meetings
Verici Dx gains shareholder backing for major share issue and LSE admission
Positive
Jun 22, 2026
Verici Dx plc, a UK- and U.S.-based precision diagnostics company specialising in AI-driven, multiomic tests for transplant patients, develops clinically validated assays such as its lead post-kidney transplant rejection test, Tutivia™, to s...
Private Placements and FinancingShareholder Meetings
Verici Dx Raises £2.6m Through Placing and WRAP Retail Offer
Positive
Jun 12, 2026
Verici Dx has completed a WRAP Retail Offer at an issue price of 0.35 pence per share, raising approximately £0.19 million through the issuance of 53,345,832 new shares to retail investors. Together with a previously announced placing of 700 ...
Private Placements and FinancingShareholder Meetings
Verici Dx calls shareholder meeting to approve new share issuance after fundraising
Neutral
Jun 8, 2026
Verici Dx plc, a developer of advanced clinical diagnostics for organ transplant patients, combines multiomic analysis with AI-driven models to deliver predictive, clinically validated tests such as its lead kidney transplant product Tutivia™...
Delistings and Listing ChangesPrivate Placements and FinancingShareholder Meetings
Verici Dx opens £200,000 retail offer after £2.5m placing
Positive
Jun 8, 2026
Verici Dx has launched a retail offer through the Winterflood Retail Access Platform to raise up to £200,000 by issuing up to 57,142,857 new shares at 0.35 pence, matching the price used in its recently completed £2.5 million placing. Th...
Private Placements and Financing
Verici Dx raises £2.5m in heavily dilutive share placing and plans retail offer
Negative
Jun 5, 2026
Verici Dx has raised approximately £2.5 million through a placing of 700 million new shares at 0.35 pence, equivalent to about 46% of its existing share capital, to support its fundraising strategy. The new shares, including a tranche intende...
Business Operations and StrategyPrivate Placements and Financing
Verici Dx launches £2.5m placing to accelerate kidney transplant test rollout
Positive
Jun 5, 2026
Verici Dx plans to raise approximately £2.5 million through a discounted placing of at least 700 million new shares, alongside a separate retail offer of up to £0.2 million, to fund the commercial scale-up of its kidney transplant diagno...
Business Operations and StrategyProduct-Related Announcements
Verici Dx Wins CPT PLA Code for Protega, Advancing U.S. Commercial Path
Positive
Jun 2, 2026
Verici Dx has secured a Proprietary Laboratory Analyses CPT code from the American Medical Association for its Protega test, effective 1 October 2026. The code, X257U, will allow the company to identify Protega more specifically when billing Medic...
Business Operations and StrategyProduct-Related Announcements
Verici Dx PTRA Kidney Transplant Test Shown to Deliver Major Cost Savings
Positive
Jun 2, 2026
Verici Dx has highlighted new peer-reviewed health economic data showing that its Pre-Transplant Risk Assessment test, marketed by Thermo Fisher Scientific, could deliver significant cost savings and clinical benefits in kidney transplantation. Th...
Business Operations and StrategyProduct-Related Announcements
Verici Dx’s transplant rejection test validated in peer-reviewed study
Positive
May 19, 2026
Verici Dx has reported that a peer-reviewed clinical validation study of its Pre-Transplant Rejection Assessment test has been published in Kidney360. The blood-based next-generation sequencing assay, marketed commercially by Thermo Fisher Scienti...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Verici Dx posts strong Q1 growth as Tutivia adoption and Medicaid coverage expand
Positive
Apr 16, 2026
Verici Dx reported a strong start to 2026, with Tutivia™ test volumes rising 32% quarter-on-quarter to 392 and 34% year-on-year in the first quarter, outpacing management expectations. Seven new transplant centres began ordering tests, a sec...
Business Operations and StrategyExecutive/Board Changes
Verici Dx Launches Board Search After Non-Executive Director Resigns
Neutral
Mar 31, 2026
Verici Dx plc, a UK- and U.S.-based precision diagnostics specialist for transplant patients, develops AI-enabled, multiomic tests such as its flagship Tutivia™ assay for early detection of acute kidney transplant rejection. Operating at the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.